AXA has acquired the shareholdings of Riemser’s founding Braun family and those of various minority stakeholders, including TVM Capital.
The amount of the transaction, whose completion is still subject to approval by the German competition authority, was not disclosed.
The company intends to use the resousces and the experience of AXA to continue to specialize and internationalize its business.
Led by Dr. Michael Mehler, CEO, Riemser focuses on the sales, marketing and lifecycle management of pharmaceutical products for niche therapeutic markets with high medical need in the fields of Oncology, Anti-Infectives and Dermatology.
The company, which has around 500 employees, markets its products in Germany and in 72 other countries.